Is hepatitis-B immunization effective during chronic liver fibrosis? Investigation of secretory and cellular immune responses on an experimental model
dc.authorid | KARACA, Zeynal Mete/0000-0002-5967-8102 | |
dc.authorid | KAYHAN, BASAK/0000-0003-3508-2563 | |
dc.authorid | Yilmaz, Sezai/0000-0002-8044-0297 | |
dc.authorwosid | KARACA, Zeynal Mete/HKM-7924-2023 | |
dc.authorwosid | KAYHAN, BASAK/ABH-9314-2020 | |
dc.authorwosid | Yilmaz, Sezai/ABI-2323-2020 | |
dc.contributor.author | Kayhan, Basak | |
dc.contributor.author | Karaca, Zeynal Mete | |
dc.contributor.author | Canpolat, Esra | |
dc.contributor.author | Ersan, Veysel | |
dc.contributor.author | Gul, Mehmet | |
dc.contributor.author | Yologlu, Saim | |
dc.contributor.author | Yilmaz, Sezai | |
dc.date.accessioned | 2024-08-04T20:53:02Z | |
dc.date.available | 2024-08-04T20:53:02Z | |
dc.date.issued | 2023 | |
dc.department | İnönü Üniversitesi | en_US |
dc.description.abstract | Objective Adults with end-stage of chronic liver diseases have lower antibody titers after hepatitis-B vaccination. We have less amount of knowledge about the effect of non-viral cause chronic liver fibrosis on vaccination. In this study, we investigated the effect of non-viral chronic liver fibrosis on hepatitis B vaccine and the effect of tetanous toxoid co-administration at the level of humoral and cellular immune responses in an experimental model. Methods Hepatitis B vaccine was administered either alone or in combination with tetanus toxoid in thioacetamide-induced fibrotic BALB/c mice. Fibrosis level was determined by Knodell scoring. Anti-HBsAg, biochemical parameters, inflammatory (IL-1 beta, TNF-alpha), and anti-inflammatory (IL-10) cytokine levels were investigated in serum samples by automated systems and ELISA; respectively. Frequencies of activated lymphocytes were determined in flow cytometer. Results Antibody titers significantly decreased after immunization of fibrotic mice. However, co-administration of toxoid significantly elevated antibody titer. The percentage of CD19(+)CD69(+) B lymphocytes was found to be lower in vaccinated fibrotic group compared to vaccinated naive group. Simultaneous administration of toxoid significantly increased the frequencies of CD4(+) and CD8(+) T cells expressing CD69 and CD127. Interestingly, CD19(+)CD5(+)CD1(high) Breg cells were significantly reduced in the group vaccinated with hepatitis B vaccine and toxoid, simultaneously. The reduction in Breg percentage did not expose a significant decrease in the level of IL-10. Conclusion Non-viral chronic liver fibrosis causes a reduction on specific antibody level after vaccination. Reduction on Breg cell frequency may have an effect on elevation of antibody level after co-administration of tetanus toxoid. | en_US |
dc.description.sponsorship | Inonu University Scientific Research Projects Unit [2016/137] | en_US |
dc.description.sponsorship | This work was supported by the Inonu University Scientific Research Projects Unit under grant number 2016/137. | en_US |
dc.identifier.doi | 10.1080/08923973.2022.2121925 | |
dc.identifier.endpage | 113 | en_US |
dc.identifier.issn | 0892-3973 | |
dc.identifier.issn | 1532-2513 | |
dc.identifier.issue | 1 | en_US |
dc.identifier.pmid | 36066099 | en_US |
dc.identifier.scopus | 2-s2.0-85138356832 | en_US |
dc.identifier.scopusquality | Q2 | en_US |
dc.identifier.startpage | 102 | en_US |
dc.identifier.uri | https://doi.org/10.1080/08923973.2022.2121925 | |
dc.identifier.uri | https://hdl.handle.net/11616/100899 | |
dc.identifier.volume | 45 | en_US |
dc.identifier.wos | WOS:000853788700001 | en_US |
dc.identifier.wosquality | Q2 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.publisher | Taylor & Francis Ltd | en_US |
dc.relation.ispartof | Immunopharmacology and Immunotoxicology | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Liver fibrosis | en_US |
dc.subject | vaccination | en_US |
dc.subject | toxoid | en_US |
dc.subject | antibody | en_US |
dc.subject | Breg | en_US |
dc.title | Is hepatitis-B immunization effective during chronic liver fibrosis? Investigation of secretory and cellular immune responses on an experimental model | en_US |
dc.type | Article | en_US |